Measles vaccination in an increasingly immunized and developed world
Increased measles immunization has led to a significant decline in measles incidence and mortality. During 2016 it is estimated that fewer than 100,000 died from measles for the first time in recorded history. In highly immunized countries measles epidemiology has changed. Threats to national elimin...
Gespeichert in:
Veröffentlicht in: | Human vaccines & immunotherapeutics 2019-01, Vol.15 (1), p.28-33 |
---|---|
1. Verfasser: | |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 33 |
---|---|
container_issue | 1 |
container_start_page | 28 |
container_title | Human vaccines & immunotherapeutics |
container_volume | 15 |
creator | Hayman, David T. S. |
description | Increased measles immunization has led to a significant decline in measles incidence and mortality. During 2016 it is estimated that fewer than 100,000 died from measles for the first time in recorded history. In highly immunized countries measles epidemiology has changed. Threats to national elimination goals and public health include aging cohorts of naïve people that exist from imperfect vaccination rates during the early years of immunization programs. This may be complemented by some loss of immunity in vaccinated populations. While childhood immunization must remain a focus for control efforts, due to higher mortality in the very young, these naïve adolescents and adults also accumulate as they age and add to the pool of susceptible people, perhaps beyond the view of those that are focused on childhood immunization. Here, features of measles epidemiology and control in highly immunized populations are reviewed, providing global data where necessary, to highlight why countries with high immunization coverage are still threatened by measles outbreaks and how changing dynamics may alter disease control. |
doi_str_mv | 10.1080/21645515.2018.1517074 |
format | Article |
fullrecord | <record><control><sourceid>proquest_infor</sourceid><recordid>TN_cdi_proquest_miscellaneous_2097596016</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_dcde232967374cd0970d178231788295</doaj_id><sourcerecordid>2097596016</sourcerecordid><originalsourceid>FETCH-LOGICAL-c534t-f33bbf2d8d1ea7a14c0f21c2cdea967b52657a87a81d72810ccf4ad0a5be5cc83</originalsourceid><addsrcrecordid>eNp9kU2PFCEQhonRuJt1f4Kmj15mpKCB7ovR7PqxyRovmngj1UCPbGgYoWfM-OtldmYn7kVCCqh66ymSl5CXQJdAO_qGgWyFALFkFLolCFBUtU_I-T6_EKL98fR0B3FGLku5o3Upylopn5MzTkHIvu3PyfUXhyW40mzRGB9x9ik2Pja4jybXoo-rsGv8NG2i_-NsrdjGuq0LaV1fv1MO9gV5NmIo7vJ4XpDvHz98u_q8uP366ebq_e3CCN7Oi5HzYRiZ7Sw4VAitoSMDw4x12Es1CCaFwq5usIp1QI0ZW7QUxeCEMR2_IDcHrk14p9fZT5h3OqHX94mUVxrz7E1w2lYo46xiuWqNpb2iFlTHeA0d60VlvT2w1pthcta4OGcMj6CPK9H_1Ku01ZJLDqKvgNdHQE6_Nq7MevLFuBAwurQpmtWZopcUZJWKg9TkVEp242kMUL03VD8YqveG6qOhte_Vv388dT3YVwXvDgIfx5QnvHdDz7gLKY8Zo_FF8__P-AsqGbAu</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2097596016</pqid></control><display><type>article</type><title>Measles vaccination in an increasingly immunized and developed world</title><source>MEDLINE</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>Hayman, David T. S.</creator><creatorcontrib>Hayman, David T. S.</creatorcontrib><description>Increased measles immunization has led to a significant decline in measles incidence and mortality. During 2016 it is estimated that fewer than 100,000 died from measles for the first time in recorded history. In highly immunized countries measles epidemiology has changed. Threats to national elimination goals and public health include aging cohorts of naïve people that exist from imperfect vaccination rates during the early years of immunization programs. This may be complemented by some loss of immunity in vaccinated populations. While childhood immunization must remain a focus for control efforts, due to higher mortality in the very young, these naïve adolescents and adults also accumulate as they age and add to the pool of susceptible people, perhaps beyond the view of those that are focused on childhood immunization. Here, features of measles epidemiology and control in highly immunized populations are reviewed, providing global data where necessary, to highlight why countries with high immunization coverage are still threatened by measles outbreaks and how changing dynamics may alter disease control.</description><identifier>ISSN: 2164-5515</identifier><identifier>EISSN: 2164-554X</identifier><identifier>DOI: 10.1080/21645515.2018.1517074</identifier><identifier>PMID: 30156949</identifier><language>eng</language><publisher>United States: Taylor & Francis</publisher><subject>Communicable Disease Control ; cost-benefit analyses ; Developed Countries - statistics & numerical data ; Disease Susceptibility ; Humans ; immunization ; Immunization Programs ; Incidence ; Measles ; Measles - epidemiology ; Measles - prevention & control ; measles containing vaccine ; Measles Vaccine - administration & dosage ; MMR ; Review ; supplementary immunization activities ; Vaccination ; Vaccination Coverage - statistics & numerical data</subject><ispartof>Human vaccines & immunotherapeutics, 2019-01, Vol.15 (1), p.28-33</ispartof><rights>2018 The Author(s). Published with license by Taylor & Francis Group, LLC 2018</rights><rights>2018 The Author(s). Published with license by Taylor & Francis Group, LLC 2018 The Author(s)</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c534t-f33bbf2d8d1ea7a14c0f21c2cdea967b52657a87a81d72810ccf4ad0a5be5cc83</citedby><cites>FETCH-LOGICAL-c534t-f33bbf2d8d1ea7a14c0f21c2cdea967b52657a87a81d72810ccf4ad0a5be5cc83</cites><orcidid>0000-0003-0087-3015</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6363159/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6363159/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30156949$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Hayman, David T. S.</creatorcontrib><title>Measles vaccination in an increasingly immunized and developed world</title><title>Human vaccines & immunotherapeutics</title><addtitle>Hum Vaccin Immunother</addtitle><description>Increased measles immunization has led to a significant decline in measles incidence and mortality. During 2016 it is estimated that fewer than 100,000 died from measles for the first time in recorded history. In highly immunized countries measles epidemiology has changed. Threats to national elimination goals and public health include aging cohorts of naïve people that exist from imperfect vaccination rates during the early years of immunization programs. This may be complemented by some loss of immunity in vaccinated populations. While childhood immunization must remain a focus for control efforts, due to higher mortality in the very young, these naïve adolescents and adults also accumulate as they age and add to the pool of susceptible people, perhaps beyond the view of those that are focused on childhood immunization. Here, features of measles epidemiology and control in highly immunized populations are reviewed, providing global data where necessary, to highlight why countries with high immunization coverage are still threatened by measles outbreaks and how changing dynamics may alter disease control.</description><subject>Communicable Disease Control</subject><subject>cost-benefit analyses</subject><subject>Developed Countries - statistics & numerical data</subject><subject>Disease Susceptibility</subject><subject>Humans</subject><subject>immunization</subject><subject>Immunization Programs</subject><subject>Incidence</subject><subject>Measles</subject><subject>Measles - epidemiology</subject><subject>Measles - prevention & control</subject><subject>measles containing vaccine</subject><subject>Measles Vaccine - administration & dosage</subject><subject>MMR</subject><subject>Review</subject><subject>supplementary immunization activities</subject><subject>Vaccination</subject><subject>Vaccination Coverage - statistics & numerical data</subject><issn>2164-5515</issn><issn>2164-554X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>0YH</sourceid><sourceid>EIF</sourceid><sourceid>DOA</sourceid><recordid>eNp9kU2PFCEQhonRuJt1f4Kmj15mpKCB7ovR7PqxyRovmngj1UCPbGgYoWfM-OtldmYn7kVCCqh66ymSl5CXQJdAO_qGgWyFALFkFLolCFBUtU_I-T6_EKL98fR0B3FGLku5o3Upylopn5MzTkHIvu3PyfUXhyW40mzRGB9x9ik2Pja4jybXoo-rsGv8NG2i_-NsrdjGuq0LaV1fv1MO9gV5NmIo7vJ4XpDvHz98u_q8uP366ebq_e3CCN7Oi5HzYRiZ7Sw4VAitoSMDw4x12Es1CCaFwq5usIp1QI0ZW7QUxeCEMR2_IDcHrk14p9fZT5h3OqHX94mUVxrz7E1w2lYo46xiuWqNpb2iFlTHeA0d60VlvT2w1pthcta4OGcMj6CPK9H_1Ku01ZJLDqKvgNdHQE6_Nq7MevLFuBAwurQpmtWZopcUZJWKg9TkVEp242kMUL03VD8YqveG6qOhte_Vv388dT3YVwXvDgIfx5QnvHdDz7gLKY8Zo_FF8__P-AsqGbAu</recordid><startdate>20190102</startdate><enddate>20190102</enddate><creator>Hayman, David T. S.</creator><general>Taylor & Francis</general><general>Taylor & Francis Group</general><scope>0YH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0003-0087-3015</orcidid></search><sort><creationdate>20190102</creationdate><title>Measles vaccination in an increasingly immunized and developed world</title><author>Hayman, David T. S.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c534t-f33bbf2d8d1ea7a14c0f21c2cdea967b52657a87a81d72810ccf4ad0a5be5cc83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Communicable Disease Control</topic><topic>cost-benefit analyses</topic><topic>Developed Countries - statistics & numerical data</topic><topic>Disease Susceptibility</topic><topic>Humans</topic><topic>immunization</topic><topic>Immunization Programs</topic><topic>Incidence</topic><topic>Measles</topic><topic>Measles - epidemiology</topic><topic>Measles - prevention & control</topic><topic>measles containing vaccine</topic><topic>Measles Vaccine - administration & dosage</topic><topic>MMR</topic><topic>Review</topic><topic>supplementary immunization activities</topic><topic>Vaccination</topic><topic>Vaccination Coverage - statistics & numerical data</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hayman, David T. S.</creatorcontrib><collection>Taylor & Francis (Open Access)</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>Directory of Open Access Journals</collection><jtitle>Human vaccines & immunotherapeutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hayman, David T. S.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Measles vaccination in an increasingly immunized and developed world</atitle><jtitle>Human vaccines & immunotherapeutics</jtitle><addtitle>Hum Vaccin Immunother</addtitle><date>2019-01-02</date><risdate>2019</risdate><volume>15</volume><issue>1</issue><spage>28</spage><epage>33</epage><pages>28-33</pages><issn>2164-5515</issn><eissn>2164-554X</eissn><abstract>Increased measles immunization has led to a significant decline in measles incidence and mortality. During 2016 it is estimated that fewer than 100,000 died from measles for the first time in recorded history. In highly immunized countries measles epidemiology has changed. Threats to national elimination goals and public health include aging cohorts of naïve people that exist from imperfect vaccination rates during the early years of immunization programs. This may be complemented by some loss of immunity in vaccinated populations. While childhood immunization must remain a focus for control efforts, due to higher mortality in the very young, these naïve adolescents and adults also accumulate as they age and add to the pool of susceptible people, perhaps beyond the view of those that are focused on childhood immunization. Here, features of measles epidemiology and control in highly immunized populations are reviewed, providing global data where necessary, to highlight why countries with high immunization coverage are still threatened by measles outbreaks and how changing dynamics may alter disease control.</abstract><cop>United States</cop><pub>Taylor & Francis</pub><pmid>30156949</pmid><doi>10.1080/21645515.2018.1517074</doi><tpages>6</tpages><orcidid>https://orcid.org/0000-0003-0087-3015</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 2164-5515 |
ispartof | Human vaccines & immunotherapeutics, 2019-01, Vol.15 (1), p.28-33 |
issn | 2164-5515 2164-554X |
language | eng |
recordid | cdi_proquest_miscellaneous_2097596016 |
source | MEDLINE; PubMed Central; Alma/SFX Local Collection |
subjects | Communicable Disease Control cost-benefit analyses Developed Countries - statistics & numerical data Disease Susceptibility Humans immunization Immunization Programs Incidence Measles Measles - epidemiology Measles - prevention & control measles containing vaccine Measles Vaccine - administration & dosage MMR Review supplementary immunization activities Vaccination Vaccination Coverage - statistics & numerical data |
title | Measles vaccination in an increasingly immunized and developed world |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-14T16%3A14%3A23IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_infor&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Measles%20vaccination%20in%20an%20increasingly%20immunized%20and%20developed%20world&rft.jtitle=Human%20vaccines%20&%20immunotherapeutics&rft.au=Hayman,%20David%20T.%20S.&rft.date=2019-01-02&rft.volume=15&rft.issue=1&rft.spage=28&rft.epage=33&rft.pages=28-33&rft.issn=2164-5515&rft.eissn=2164-554X&rft_id=info:doi/10.1080/21645515.2018.1517074&rft_dat=%3Cproquest_infor%3E2097596016%3C/proquest_infor%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2097596016&rft_id=info:pmid/30156949&rft_doaj_id=oai_doaj_org_article_dcde232967374cd0970d178231788295&rfr_iscdi=true |